Zevra Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Zevra Therapeutics

03/11/2023 15:37

* Zevra Therapeutics Inc  ZVRA.OQ   ZVRA.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Celebration Florida-based  company is expected to
report  a
17.6% increase in revenue to $3.379 million from $2.87 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Zevra Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zevra
Therapeutics Inc is $20​, above​ its last closing price
of $4.41. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.37       -0.34      -0.15     Beat    56.3
 Mar. 31 2023  -0.24       -0.23      -0.34     Missed  -46.2
 Dec. 31 2022  -0.17       -0.17      -0.26     Missed  -50​
 Sep. 30 2022  -0.13       -0.13      -0.19     Missed  -46.2
 ​​Jun.        -0.12       -0.12      -0.19     Missed  -58.3
 30 2022                                                
 Mar. 31 2022  -0.05       -0.05      -0.05     Met     9.1​
 Dec. 31 2021  -0.10       -0.07      -0.08     Missed  -6.7
 Sep. 30 2021  -0.09       -0.07      -0.05     Beat    33.3
 This summary was machine generated November 3 at 15:37 GMT.  All
figures in US dollars  unless otherwise stated